恒瑞医药HRS - 9231注射液启动III期临床 适应症为成人中枢神经系统外病变磁共振成像

新浪财经
Nov 04

药物临床试验登记与信息公示平台数据显示,江苏恒瑞医药股份有限公司/上海盛迪医药有限公司的评价HRS - 9231用于身体部位(中枢神经系统除外)磁共振成像(MRI)的有效性与安全性的多中心、随机、双盲、阳性对照、交叉对照III期临床试验已启动。临床试验登记号为CTR20254396,首次公示信息日期为2025年11月4日。该药物剂型为注射液,规格为10ml:4g/瓶,用法用量为静脉注射,单次用药。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10